Bioxodes appoints Dr. Hans Warrinnier as Chief Medical Officer

Bioxodes announces the completion of the active phase of its First-in-Human study performed in healthy adult volunteers with Ir-CPI

Bioxodes obtains authorization to launch Phase I trial of its antithrombotic drug, Ir-CPI, in healthy male volunteers

Bioxodes raises EUR 7.65 million to cover its clinical Phase I study and to obtain first proofs of efficacy in patients

Bioxodes raises EUR 7.9 million to bring Ir-CPI to the clinic

Bioxodes’ antithrombotic meets development milestones – Company to launch Series A financing round to bring product to the clinic

Bioxodes raises EUR 2.6 million to develop antithrombotic peptide derived from tick saliva